Form 6-K Cellect Biotechnology For: Sep 26

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: September 2016 (Report No. 7)

 

Commission file number: 001-37846

 

CELLECT BIOTECHNOLOGY LTD.

(Translation of registrant's name into English)

 

23 Hata’as Street

Kfar Saba, Israel 44425

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x        Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ¨

 

 

 

 

On September 25, 2016, Cellect Biotechnology Ltd. (the “Company”) held an extraordinary general meeting (the “Meeting”) of the holders of the Company’s American Depositary Shares (the “ADSs”). At the Meeting, the holders of the Company’s ADSs passed all agenda items as originally proposed.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

		Cellect Biotechnology Ltd. (Registrant)   By /s/ Dr. Shai Yarkoni
		Name: Dr. Shai Yarkoni
		Chief Executive Officer

 

Date: September 26, 2016

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Biophytis Announces Transfer of ADSs to OTC Market
• Aurania Announces Increase in Size of Debt Settlement to C$2.07 Million
• Highline Recognizes Eleven Townships in Michigan’s Menominee County for being Designated as Smart Rural Communities